Lead: A randomized crossover trial led by Prof. Olga Ramich at the German Institute of Human Nutrition (DIfE) and Charité—Universitätsmedizin Berlin, published 28 December 2025 in Science Translational Medicine, tested eight‑hour time‑restricted eating (TRE) in an isocaloric setting. Over two two‑week intervention periods, 31 women with overweight or obesity followed early (8:00–16:00) and late (13:00–21:00) eating windows while consuming nearly identical calories and nutrients. The trial found no clinically meaningful improvements in insulin sensitivity, glycemia, blood lipids, or inflammatory markers when calorie intake was held constant. Meal timing did, however, shift participants’ internal circadian timing by roughly 40 minutes on average.
Key takeaways
- The ChronoFast trial randomized 31 women with overweight or obesity to early TRE (8:00–16:00) and late TRE (13:00–21:00) in a crossover design, with each phase lasting two weeks.
- Diet was isocaloric across conditions: participants consumed nearly identical meals by calorie and macronutrient composition during both windows.
- No clinically meaningful changes were observed in insulin sensitivity, 24‑hour glucose profiles, fasting blood lipids, or common inflammatory markers after either two‑week phase.
- Continuous glucose monitoring, oral glucose tolerance tests, and motion sensors were used to track metabolism and activity throughout the study.
- Blood‑cell analyses using the BodyTime assay showed an average ~40‑minute shift in internal circadian phase during the late eating window compared with the early window.
- The authors conclude prior reported benefits from TRE likely reflected unintended calorie reduction rather than meal timing alone.
- The trial highlights that calorie balance and individual chronobiology may be critical determinants of TRE’s metabolic effects.
Background
Time‑restricted eating (TRE) limits food intake to a defined daily window — typically 10 hours or less — followed by an overnight fast of at least 14 hours. TRE has grown popular as a simple strategy thought to aid weight management and improve cardiometabolic health without requiring detailed calorie counting. Animal models, particularly in rodents, have shown robust protection from diet‑induced obesity and metabolic dysfunction when feeding is restricted to an active phase, even when caloric intake is unchanged.
Human studies, however, have produced mixed results. Some trials reported improved insulin sensitivity, lower fasting glucose and cholesterol, and modest weight or fat loss; others found little or no benefit. A persistent methodological gap has been inadequate control of calorie intake and inconsistent measurement of confounders such as physical activity and sleep timing. Those limitations make it difficult to separate effects of meal timing from those of spontaneous calorie reduction that often accompany TRE.
Main event
The ChronoFast trial was designed to isolate the effect of eating window timing from energy intake. Thirty‑one adult women with overweight or obesity completed two two‑week interventions in randomized order: early TRE (8:00–16:00) and late TRE (13:00–21:00). Meals were matched for calories and nutrient composition across conditions to maintain an isocaloric intake.
Investigators used oral glucose tolerance tests and frequent blood sampling during four clinic visits to assess glucose and lipid metabolism. Participants wore continuous glucose monitors and motion sensors, and they logged all food intake. In collaboration with Prof. Achim Kramer, the team applied the BodyTime assay to blood cells to determine each participant’s internal circadian phase from a single sample.
After comparing measures collected at the end of each intervention, the study team found no clinically meaningful changes in insulin sensitivity, 24‑hour glycemic control, fasting blood lipids, or selected inflammatory markers attributable to shifting the eating window alone. The randomized crossover design and careful control of calories strengthen the conclusion that timing by itself did not drive metabolic improvements in this cohort over the short interventions used.
Meal timing did produce measurable circadian effects: the BodyTime assay detected an average 40‑minute later internal phase during the late TRE condition, and actigraphy/diary data showed later bed and wake times among participants following the later window. These findings indicate feeding schedules can entrain peripheral and behavioral rhythms even when energy intake is unchanged.
Analysis & implications
The ChronoFast results emphasize that energy balance remains a dominant factor for short‑term metabolic outcomes. If TRE leads people to eat fewer calories in real‑world settings, metabolic improvements reported in prior trials may be attributable to that calorie reduction rather than the restricted window itself. For clinicians and people using TRE as a tool, the study suggests monitoring total energy intake is essential when the goal is weight loss or better insulin sensitivity.
Separately, the documented shifts in internal timing are biologically meaningful. Meal timing acts as a zeitgeber (time cue) for peripheral clocks, which coordinate tissue‑level metabolism. A consistent shift of ~40 minutes across blood‑cell clocks in response to a later eating window could interact with sleep timing, medication schedules, and glucose regulation in ways that require longer studies to clarify.
Policy and guidance that promote TRE as a simple clock‑only intervention for metabolic health should be tempered: without concurrent attention to calorie intake and individual factors such as chronotype, the metabolic return appears limited over the short term. Future trials need longer interventions, mixed‑sex samples, and participants with established metabolic disease to test whether sustained meal‑timing strategies yield clinically relevant benefits.
Comparison & data
| Feature | Typical prior TRE studies | ChronoFast |
|---|---|---|
| Design | Parallel or crossover, varying duration | Randomized crossover, two 2‑week phases |
| Calorie control | Often ad libitum or incompletely tracked | Isocaloric meals matched across conditions |
| Sample | Mixed sizes, variable sex/age | 31 women with overweight/obesity |
| Primary outcome | Insulin sensitivity, weight, lipids | Insulin sensitivity, glucose, lipids, inflammation, circadian phase |
| Main finding | Mixed — some metabolic benefits reported | No metabolic benefit when calories unchanged; ~40‑min circadian shift |
This table contrasts ChronoFast’s tighter calorie control and circadian readout against the more heterogeneous methods used in many earlier TRE trials. The stronger dietary control in ChronoFast reduces confounding from spontaneous calorie reductions, which plausibly explains differences between studies.
Reactions & quotes
Investigators characterized the results as a refinement of how TRE should be interpreted — not a wholesale rejection of its value. Below are representative statements placed in context.
“Our results suggest that the health benefits observed in earlier studies were likely due to unintended calorie reduction, rather than the shortened eating period itself.”
Prof. Olga Ramich, DIfE/Charité (lead investigator)
Ramich’s summary underscores the trial’s primary conclusion: when energy intake is matched, the short‑term metabolic markers measured did not improve. She and colleagues call for studies that combine TRE with calorie reduction to test additive effects.
“The timing of food intake acts as a cue for our biological rhythms — similar to light.”
Beeke Peters (first author)
Peters’ comment accompanies the BodyTime data showing a consistent shift in internal timing. The team notes this entrainment may have downstream effects that require longer follow‑up to detect.
“BodyTime offers a practical, one‑sample readout of internal phase that can help map how lifestyle cues affect peripheral clocks.”
Prof. Achim Kramer, Charité (circadian method developer)
Kramer framed the methodological advance: the BodyTime assay enabled objective, scalable measurement of circadian phase in this clinical trial.
Unconfirmed
- Whether longer TRE interventions (several months) without calorie reduction might produce metabolic benefits remains untested in this cohort and is unconfirmed.
- It is unconfirmed whether the null metabolic result generalizes to men, younger or older adults, or people with established type 2 diabetes or advanced metabolic disease.
- The clinical significance of a ~40‑minute shift in peripheral circadian phase for long‑term cardiometabolic risk is currently unknown and requires further study.
Bottom line
ChronoFast refines our understanding of TRE by showing that, over short two‑week exposures in an isocaloric setting, shifting an eight‑hour eating window does not improve insulin sensitivity, glycemia, blood lipids, or inflammatory markers in women with overweight or obesity. The trial’s design — randomized crossover with tight calorie matching — strengthens the inference that earlier reported metabolic gains may have been driven by reduced energy intake rather than timing alone.
At the same time, meal timing meaningfully shifted internal circadian phase, indicating biological sensitivity to feeding schedules. For individuals and clinicians, the pragmatic implication is clear: if the goal is metabolic improvement or weight loss, attention to total caloric intake remains essential. Future studies should test longer interventions, mixed‑sex samples, and combinations of TRE with calorie reduction to determine whether timing adds benefit beyond energy balance.
Sources
- ScienceDaily — media report summarizing ChronoFast (secondary news coverage)
- Science Translational Medicine — peer‑reviewed journal (journal homepage for the publishing venue)
- German Institute of Human Nutrition (DIfE) (institutional; lead research institute)
- Charité — Universitätsmedizin Berlin (institutional; clinical collaborator)